Alan DAndrea
Overview
Explore the profile of Alan DAndrea including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
3829
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Szallasi Z, Diossy M, Tisza V, Li H, Sahgal P, Zhou J, et al.
Res Sq
. 2024 Apr;
PMID: 38645014
We analyzed genomic data derived from the prostate cancer of African and European American men in order to identify differences that may contribute to racial disparity of outcome and that...
2.
Swisher E, Rayes N, Bowen D, Peterson C, Norquist B, Coffin T, et al.
JAMA Oncol
. 2023 Sep;
9(11):1547-1555.
PMID: 37707822
Importance: Requiring personalized genetic counseling may introduce barriers to cancer risk assessment, but it is unknown whether omitting counseling could increase distress. Objective: To assess whether omitting pretest and/or posttest...
3.
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
Ingham M, Allred J, Chen L, Das B, Kochupurakkal B, Gano K, et al.
J Clin Oncol
. 2023 Jul;
41(25):4154-4163.
PMID: 37467452
Purpose: Uterine leiomyosarcoma (uLMS) is an aggressive subtype of soft-tissue sarcoma with frequent metastatic relapse after curative surgery. Chemotherapy provides limited benefit for advanced disease. Multiomics profiling studies have identified...
4.
Coffin T, Bowen D, Swisher E, Lu K, Rayes N, Norquist B, et al.
JMIR Form Res
. 2022 Oct;
6(10):e34055.
PMID: 36251350
Background: Genetic testing uptake is low, despite the well-established connection between pathogenic variants in certain cancer-linked susceptibility genes and ovarian cancer risk. Given that most major insurers cover genetic testing...
5.
Coffin T, Bowen D, Lu K, Swisher E, Rayes N, Norquist B, et al.
JMIR Form Res
. 2022 Sep;
6(9):e35035.
PMID: 36155347
Background: Strong participant recruitment practices are critical to public health research but are difficult to achieve. Traditional recruitment practices are often time consuming, costly, and fail to adequately target difficult-to-reach...
6.
Pollard J, Furutani E, Liu S, Esrick E, Cohen L, Bledsoe J, et al.
Blood Adv
. 2022 May;
6(12):3803-3811.
PMID: 35500223
Fanconi anemia (FA), a genetic DNA repair disorder characterized by marrow failure and cancer susceptibility. In FA mice, metformin improves blood counts and delays tumor development. We conducted a single...
7.
Batalini F, Xiong N, Tayob N, Polak M, Eismann J, Cantley L, et al.
Clin Cancer Res
. 2022 Feb;
28(8):1493-1499.
PMID: 35149538
Purpose: We had previously reported on the safety and the recommended phase 2 dose (RP2D) of olaparib in combination with the PI3Kα-specific inhibitor alpelisib in patients with high-grade serous ovarian...
8.
Keenan T, Li T, Vallius T, Guerriero J, Tayob N, Kochupurakkal B, et al.
Clin Cancer Res
. 2020 Dec;
27(4):983-991.
PMID: 33257427
Purpose: We report results from a phase II study assessing the efficacy of the WEE1 inhibitor adavosertib with cisplatin in metastatic triple-negative breast cancer (mTNBC). Patients And Methods: Patients with...
9.
Tung N, Robson M, Ventz S, Santa-Maria C, Nanda R, Marcom P, et al.
J Clin Oncol
. 2020 Oct;
38(36):4274-4282.
PMID: 33119476
Purpose: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) in germline (g)/ mutation...
10.
Carbone M, Arron S, Beutler B, Bononi A, Cavenee W, Cleaver J, et al.
Nat Rev Cancer
. 2020 May;
20(9):533-549.
PMID: 32472073
Cell division and organismal development are exquisitely orchestrated and regulated processes. The dysregulation of the molecular mechanisms underlying these processes may cause cancer, a consequence of cell-intrinsic and/or cell-extrinsic events....